Keyword: Sun Pharmaceutical
Here is some news of note for the week.
Merck halves Keytruda's price in China; Takeda eyes selling Shire's Xiidra and Natpara; another ex-GSK scientist pleads guilty to trade secret theft.
India’s Sun Pharmaceuticals, which is working to shift its focus to novel and specialty drugs, has won FDA approval of a new treatment for glaucoma.
Novartis has been battling claims it illegally protected Gleevec's market, but this week the drugmaker prevailed in the cases.
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.
After more than two years of intense effort, Sun Pharma has returned its key plant to the good graces of the FDA.
Takeda investors voice concerns over Shire deal; WuXi AppTec becomes the largest-cap CRO; two families' wealth swells on Gardasil nods.
The chairman of Zhifei Biological Products, which holds Chinese rights to Gardasil and Gardasil 9, boasted a net worth of about $4.6 billion Wednesday.
Sun Pharma, India's largest drug manufacturer, said pricing pressure in its generics market targeting the U.S. may lead to lower 2019 revenues.
Astellas plots 600 job cuts in Japan; GSK's infectious disease lead launches a Chinese biotech; Sun Pharma's Zytiga rival wins the FDA's blessing.